Holen Sie sich die Stockscreener-App
2.66
0.00%
0.00
Vorhandelsmarkt:
2.69
0.03
+1.13%
Cervomed Inc Aktie (CRVO) Neueste Nachrichten
CervoMed Inc (CRVO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CervoMed Inc (CRVO) Cash Flow - TradingKey
CervoMed Inc (CRVO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CervoMed Inc (CRVO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
CRVO|CervoMed Inc|Price:2.690|Chg%:+0.030 - TradingKey
CRVO|CervoMed Inc|Price:2.640|Chg%:-0.020 - TradingKey
CervoMed Inc (CRVO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
CervoMed Inc (CRVO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CervoMed Inc (CRVO) Valuation: PE, PB & Fair Value Analysis - TradingKey
CervoMed Inc (CRVO) Income Statement - TradingKey
CervoMed Inc. Revenue Breakdown – NASDAQ:CRVO - TradingView
CRVO|CervoMed Inc|Price:2.660|Chg%:-0.010 - TradingKey
Matt Winton Says Most Biotechs Are Not the Best to Launch Their Own Drugs — and That’s a Strength, Not a Failure - finance.biggo.com
Insiders the Biggest Winners as CervoMed Inc.'s (NASDAQ:CRVO) Market Cap Rises to US$151m - 富途牛牛
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target - Investing.com UK
H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target By Investing.com - Investing.com South Africa
CRVO Reiterated by HC Wainwright & Co. -- Rating Maintained at B - GuruFocus
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CervoMed Inc. Announces New Clinical Data for Neflamapimod in Dementia with Lewy Bodies at AAIC 2026 - Minichart
CervoMed (NASDAQ: CRVO) highlights DLB trial data and Phase 3 plans - Stock Titan
CervoMed selects 50 mg Phase 3 dose - grafa.com
CervoMed presents dementia drug data at AAIC 2026 conference By Investing.com - Investing.com Nigeria
CervoMed Inc. Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in Treatment of Dementia with Lewy Bodies - marketscreener.com
CervoMed presents dementia drug data at AAIC 2026 conference - Investing.com
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB) - The Manila Times
CervoMed Announces New Clinical, Plasma Biomarker and - GlobeNewswire
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment - Investing.com UK
H.C. Wainwright reiterates CervoMed stock rating on trial enrollment By Investing.com - Investing.com Australia
CRVO Reiterates Buy Rating by HC Wainwright -- Price Target Main - GuruFocus
CervoMed Inc. SEC Filing (Jul 13, 2026) - Stock Titan
CervoMed (NASDAQ: CRVO) registers 10,081,131 private placement shares for resale - Stock Titan
CervoMed Completes Phase 2 Enrollment of Neflamapimod for Frontotemporal Dementia; Interim Data Accepted at CTAD Conference 9 – Minichart - Minichart
CervoMed completes enrollment in Phase 2a nfvPPA trial; interim biomarker data slated for CTAD - TradingView
CervoMed (NASDAQ: CRVO) finishes Phase 2a nfvPPA enrollment and schedules CTAD data - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
CervoMed finalizes Phase 2a enrollment for nfvPPA frontotemporal dementia - grafa.com
CervoMed (CRVO) Completes Enrollment in Phase 2a Study for nfvPP - GuruFocus
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target By Investing.com - Investing.com South Africa
CervoMed completes enrollment in phase 2a nfvPPA trial By Investing.com - Investing.com South Africa
CervoMed Completes Enrollment in Phase 2a Study of Neflamapimod in Frontotemporal Dementia - Moomoo
CervoMed completes enrollment in phase 2a nfvPPA trial - Investing.com
H.C. Wainwright reiterates Buy on CervoMed stock, $25 target - Investing.com India
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia - The Manila Times
CervoMed finishes Phase 2 study in rare dementia with no U.S. or EU treatment - Stock Titan
CRVO Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue R&D InvestmentEBITDA Margin Trends - dars.gov.et
Morgan Stanley Ceases >5% Beneficial Ownership in CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed Q1 2026 Earnings: EPS Misses Estimates, Stock Rallies 1.46% Amid Pipeline ProgressEarnings Stability Report - dars.gov.et
Cash flow from operating activities of CervoMed Inc. – DUS:DP8 - TradingView
CervoMed files prospectus for offer and resale of 10.08M shares - scanx.trade
Form S-3 CervoMed Inc For: 6 July By Investing.com - Investing.com Nigeria
CRVO Set to Offer 10.08 Million Shares for Sale - GuruFocus
1.97%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):